Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

INTI FERNANDEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1659461101
CMS profile
75387
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$68.75

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $68.75 4

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Nestle HealthCare Nutrition Inc. $30.02 2
AstraZeneca Pharmaceuticals LP $23.03 1
Amgen Inc. $15.70 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

INTI FERNANDEZ

NPI 1659461101 · CMS profile ID 75387

Allopathic & Osteopathic Physicians / General Practice

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659461101?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659461101?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659461101?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
INTI FERNANDEZ, NPI 1659461101, CMS profile ID 75387, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659461101?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $68.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $15.7009/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825364767 CMS
Nestle HealthCare Nutrition Inc. $16.6705/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820894909 CMS
AstraZeneca Pharmaceuticals LP $23.0304/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829594137 CMS
Nestle HealthCare Nutrition Inc. $13.3504/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820894905 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.06 4
PY2020 $15.80 1
PY2021 $68.75 4
PY2022 $37.69 2
PY2023 $109.38 6
PY2024 $406.19 11
PY2025 $104.22 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $247,458.00 56
PY2024 Principal investigator $394,912.46 60
PY2023 Principal investigator $216,893.52 51
PY2022 Principal investigator $150,151.52 34
PY2021 Principal investigator $179,866.77 30
PY2020 Principal investigator $179,109.45 79
PY2019 Principal investigator $44,348.58 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998414405
Principal investigator 1 ABBVIE INC. $927.00 12/31/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension No dispute reported 06/30/2026 998414415
Principal investigator 1 ABBVIE INC. $804.00 12/31/2023 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 998414429
Principal investigator 1 ABBVIE INC. $11,031.00 12/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998409867
Principal investigator 1 ABBVIE INC. $2,409.00 11/07/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998406433
Principal investigator 1 ABBVIE INC. $5,114.75 11/07/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998406905
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $13,822.79 10/25/2023 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1059419713
Principal investigator 1 ABBVIE INC. $8,256.25 10/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998401771
Principal investigator 1 ABBVIE INC. $914.00 10/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998401835
Principal investigator 1 ABBVIE INC. $4,084.00 10/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998401837
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $14,408.89 09/13/2023 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1059418871
Principal investigator 1 ABBVIE INC. $2,042.00 09/05/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998397935
Principal investigator 1 ABBVIE INC. $5,459.00 09/05/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998397937
Principal investigator 1 ABBVIE INC. $9,381.25 09/05/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998397939
Principal investigator 1 ABBVIE INC. $2,018.75 08/09/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998393483
Principal investigator 1 ABBVIE INC. $1,921.00 08/09/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998394303
Principal investigator 1 ABBVIE INC. $7,706.00 08/09/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998394305
Principal investigator 1 ABBVIE INC. $1,950.00 07/03/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 998389191
Principal investigator 1 ABBVIE INC. $3,656.00 07/03/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998389193
Principal investigator 1 ABBVIE INC. $6,380.00 07/03/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998389195
Principal investigator 1 Cue Health Inc. $8,797.00 06/30/2023 Non-covered Recipient Entity
PharmaSeek LLC
Strep No dispute reported 06/30/2026 995803055
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $11,500.00 06/09/2023 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1059418247
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,000.00 06/09/2023 Non-covered Recipient Entity
Valencia Medical and Research Center
C3300-201 No dispute reported 06/30/2026 1059418253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $579.58 06/08/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977115565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,299.78 06/08/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977115571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,194.97 05/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977111121
Principal investigator 1 ABBVIE INC. $2,524.00 05/16/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998383781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,517.27 05/09/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977107461
Principal investigator 1 ABBVIE INC. $2,170.00 05/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 998381433
Principal investigator 1 ABBVIE INC. $10,421.00 05/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998381435
Principal investigator 1 ABBVIE INC. $1,850.00 05/04/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998381437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 04/13/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977103703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/13/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977103709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 04/13/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977103715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.14 03/29/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977101243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,092.50 03/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977100873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.40 03/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977100897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 03/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977100909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.80 03/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977100915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,900.00 03/24/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977100921
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,880.40 03/15/2023 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 991130725
Principal investigator 1 ABBVIE INC. $1,244.00 03/09/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998373669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 02/28/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977094039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 02/28/2023 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA FOR THE PREVENTION OF RECURRENT ACUTE PANCREATITIS No dispute reported 06/30/2026 977094045
Principal investigator 1 ABBVIE INC. $11,639.00 02/22/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998371587
Principal investigator 1 ABBVIE INC. $6,447.00 02/22/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998371589
Principal investigator 1 ABBVIE INC. $1,021.00 02/02/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998368219
Principal investigator 1 ABBVIE INC. $1,085.00 02/02/2023 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTE
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 998368267
Principal investigator 1 ABBVIE INC. $8,265.00 01/11/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 998364843
Principal investigator 1 ABBVIE INC. $6,623.00 01/11/2023 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTE
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children No dispute reported 06/30/2026 998364845
Principal investigator 1 ABBVIE INC. $8,500.00 01/11/2023 Non-covered Recipient Entity
VALENCIA MEDICAL & RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998364847